Drug Profile
KD 027
Alternative Names: KD027; SLX 2101; SLx-2101Latest Information Update: 20 Aug 2015
Price :
$50
*
At a glance
- Originator Surface Logix
- Developer Kadmon Pharmaceuticals; Surface Logix
- Class Cardiovascular therapies; Erectile dysfunction therapies; Small molecules
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Erectile dysfunction; Hypertension; Raynaud's disease
Most Recent Events
- 14 Apr 2014 KD 027 is still in phase II trials for Hypertension
- 14 Apr 2014 Discontinued - Phase-II for Erectile dysfunction in USA (PO)
- 14 Apr 2014 Discontinued - Phase-II for Raynaud's disease in Germany (PO)